NICEATM
This article was originally published in The Rose Sheet
Executive Summary
No public comments were received on the "Addendum to the ICCVAM Evaluation of In Vitro Test Methods for Detecting Potential Endocrine Disruptors: Estrogen Receptor and Androgen Receptor Binding and Transcriptional Activation Assays," the National Toxicology Program Interagency Center for the Evaluation of Alternative Toxicological Methods states in a Sept. 28 Federal Register 1notice. The document is available on the NICEATM Web site. NTP had requested comments on the addendum when it was published in a March 16 Federal Register notice. The addendum proposed replacing four substances from a list proposed for validation of the screening methods (2"The Rose Sheet" March 20, 2006, In Brief)...
You may also be interested in...
ICCVAM
Addendum to the ICCVAM Evaluation of In Vitro Test Methods for Detecting Potential Endocrine Disruptors: Estrogen Receptor and Androgen Receptor Binding and Transcriptional Activation Assays published in a March 16 Federal Register notice includes recommendation by Interagency Coordinating Committee on the Validation of Alternative Methods to replace four substances that are not commercially available or have restricted availability - anastrazole, CGS 18320B, fadrozole and ICI 182,780 - with 4-hydroxyandrostenedione, chrysin, dicofol and raloxifene HCl. ICCVAM published final report containing minimum procedural standards for standardization and validation of in vitro estrogen and androgen receptor binding and transcriptional activation assays in 2003 (1"The Rose Sheet" June 16, 2003, In Brief). Comments on addendum, which also identifies six other substances that could be replaced, are due May 1...
California Court’s Inaction On TiO2 Prop 65 First Amendment Case Breeds New Lawsuits
The Personal Care Products Council seeks to stem the rising tide of titanium dioxide Proposition 65 lawsuits, requesting that a California court prohibit the state’s Attorney General and private enforcers from filing and/or prosecuting new suits against cosmetics companies failing to warn about potential TiO2 exposure.
Kenvue Breaks Ground On New Headquarters, Appoints Chief Corporate Affairs Officer
Firm hosts groundbreaking for 290,000 square-foot global headquarters it’s having built in Summit, NJ, starting with 100,000 square-foot science and innovation and expected to open in 2025. It announced adding Russell Dyer as chief corporate affairs officer starting 13 March.